Clinical Trial Update: Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) [Phase 2]

View source ↗

Summary

Phase 2 ENRICH trial evaluating regimens containing BRII-179, BRII-835, and PEG-IFNα for chronic hepatitis B; the study is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• BRII-179
• BRII-835
• PEG-IFNα (pegylated interferon alfa)

Snippet

Sponsor: Brii Biosciences Limited | Conditions: For Treatment of Chronic Hepatitis B Virus Infection | Phase 2 | Status: ACTIVE_NOT_RECRUITING